Fosaprepitant for the Prevention of Nausea and Emesis During Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma
Status:
Recruiting
Trial end date:
2021-04-11
Target enrollment:
Participant gender:
Summary
This is an opene-label, single center, randomized prospective pilot study to compare the
efficacy of weekly versus triweekly fosaprepitant regimens for the prevention of nausea and
emesis during concurrent chemoradiotherapy for nasopharyngeal carcinoma (NPC).